SCHEMBL2495867

SCHEMBL2495867

COC(=O)C[C@H](c1cccc(OCc2ccccc2)c1)c1ccon1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.50
KMT2A Q03164 2/20 0.50
CTSA P10619 1/20 0.46
FFAR1 O14842 1/20 0.45
ALOX5 P09917 1/20 0.44
MAOB P27338 3/20 0.44
GPR132 Q9UNW8 3/20 0.43
NR4A2 P43354 1/20 0.43
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
SMPD1 P17405 1/20 0.42
MEN1 O00255 1/20 0.42
BCHE P06276 1/20 0.42
HIF1A Q16665 1/20 0.41
PTGES O14684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2499931 1.00 SMN1; SMN2 (0.50) SMN1; SMN2KMT2ACTSAFFAR1ALOX5
SCHEMBL2495385 0.89 SMN1; SMN2 (0.60) SMN1; SMN2KMT2ACTSAFFAR1ALOX5
SCHEMBL2500865 0.89 SMN1; SMN2 (0.60) SMN1; SMN2KMT2ACTSAFFAR1ALOX5
SCHEMBL2499306 0.83 FFAR1 (0.38) CTSAFFAR1LMNATSHRHIF1A
SCHEMBL27810369 0.83 FFAR1 (0.38) CTSAFFAR1LMNATSHRHIF1A
SCHEMBL14567338 0.81 FFAR1 (0.53) SMN1; SMN2FFAR1MAOBHTT
SCHEMBL2495871 0.80 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AFFAR1ALOX5MAOB
SCHEMBL8770884 0.79 KMT2A (0.60) SMN1; SMN2KMT2AALOX5MAOBNR4A2
SCHEMBL22668379 0.78 FFAR1 (0.51) SMN1; SMN2FFAR1MAOBHTT
SCHEMBL12194206 0.78 CTSA (0.49) KMT2ACTSAFFAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed
EP-2205548-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS Amgen, Inc (US) 2010-07-14 EP disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 US disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 US disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 US disclosed
WO-2009048527-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS AMGEN INC. (US) 2009-04-16 WO disclosed
WO-2009048527-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS AMGEN INC. (US) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137561-A1 Substituted biphenyl GPR40 modulators GPR119, GPR65, GPR55 SMN1; SMN2 4745/4885KMT2A 3040/4885CTSA 2693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.